Rational approach to the treatment for heterozygous familial hypercholesterolemia in childhood and adolescence: A review

Journal of Endocrinological Investigation

Volumn 30, Issue 8, 2007, Pages 700-719

  Lughetti, Lorenzo ^a   Predieri, B ^a   Balli, F ^a   Calandra, S ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Bile acid binding resin; Children; Diet; Familial hypercholesterolemia; HMG CoA reductase inhibitor; LDL and LDL receptor gene

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; ATORVASTATIN; COLESTILAN; COLESTIPOL; COLESTYRAMINE; ERYTHROMYCIN; FOLIC ACID; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MANNAN; MEVINOLIN; NICOTINIC ACID; PHYTOSTEROL; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN; SITOSTANOL; STANOL ESTER; STEROL; TRIACYLGLYCEROL; UNINDEXED DRUG; VITAMIN D;

ABDOMINAL PAIN; ADOLESCENT DISEASE; ANTIOXIDANT ACTIVITY; ARTHRALGIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHILDHOOD DISEASE; CHROMOSOME 19; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DIET RESTRICTION; DIETARY FIBER; DIETETICS; DISEASE ASSOCIATION; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOTHELIAL DYSFUNCTION; FAMILIAL HYPERCHOLESTEROLEMIA; FAT INTAKE; FATIGUE; FLATULENCE; GENE CLUSTER; GENE LOCATION; HEARTBURN; HEPATITIS; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INSOMNIA; JAUNDICE; LIGAND BINDING; LOW DRUG DOSE; MUSCLE CRAMP; MUSCLE RIGIDITY; MYALGIA; MYOPATHY; NAUSEA; PAIN; PALATABILITY; PATIENT COMPLIANCE; PATIENT COUNSELING; PILL; POINT MUTATION; POWDER; PRURITUS; REVIEW; RHABDOMYOLYSIS; RISK REDUCTION; SIDE EFFECT; SLEEP DISORDER; TABLET; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VITAMIN SUPPLEMENTATION; VOMITING; ADOLESCENT; CHILD; DIET THERAPY; GENETICS; HETEROZYGOTE; HYPERLIPOPROTEINEMIA TYPE 2; PRACTICE GUIDELINE;

ADOLESCENT; ANTICHOLESTEREMIC AGENTS; CHILD; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; PRACTICE GUIDELINES;

EID: 35448994868     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03347453     Document Type: Review

References (135)

1. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, et al, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill. 2001, 2863-913.
2. Kwiterovich PO Jr, Fredrickson DS, Levy RI. Familial hypercholesterolemia (one form of familial type II hyperlipoproteinemia). A study of its biochemical, genetic and clinical presentation in childhood. J Clin Invest 1974, 53: 1237-49.
3. Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965, 31: 321-7.
4. Brown MS, Goldstein JL. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. Proc Natl Acad Sci USA 1979, 76: 3330-7.
5. Packard CJ, Shepherd J. Physiology of the lipoprotein transport system: an overview of lipoprotein metabolism. In: Betteridge DJ, Illingworth DR, Shepherd J eds: Lipoproteins in health and disease. New York: Oxford University Press 1999, 17-30.
6. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992, 1: 445-66.
7. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232: 34-47.
8. LDLR Home (http://www.ucl.ac.uk/fh).
9. Van der Westhuyzen DR, Fourie AM, Coetzee CA, Gevers W. The LDL receptor. Curr Opinion Lipidol 1990, 1: 128-35.
10. Bertolini S, Cassanelli S, Garuti R, et al. Analysis of LDL receptor gene mutations in Italian patients with homozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1999, 19: 408-18.
11. Bertolini S, Cantafora A, Averna M, et al. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype. Arterioscler Thromb Vasc Biol 2000, 20: E41-52.
12. 0-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia. Arterioscler Thromb Vasc Biol 2000, 20: 236-43.
13. Calandra S, Bertolini S, Pes G, et al. Beta-thalassemia is a modifying factor of the clinical expression of familial hypercholesterolemia. Semin Vasc Med 2004, 4: 271-8.
14. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985, 37: 268-85.
15. Wiegman A, Sijbrands EJ, Rodenburg J, et al. The apolipoprotein epsilon4 allele confers additional risk in children with familial hypercholesterolemia. Pediatr Res 2003, 53: 1008-12.
16. National Choesterol Education Program. Report of the Expert Panel on Blood Cholesterol in Children and Adolescents. Bethesda, MD: National Cholesterol Education Program, 1991.
17. American Academy of Pediatrics. National Cholesterol Education Program: Report of the Expert Panel on Blood Cholesterol Levels in Children and Adolescents. Pediatrics 1992, 89: 525-84.
18. Wiegman A, Rodenburg J, de Jongh S, et al. Family history and cardiovascular risk in familial hypercholesterolemia: data in more than 1000 children. Circulation 2003, 107: 1473-8.
19. Berenson GS, Srinivasan SR, Bao W, Newman WP, Tracy RE, Wattingney WA. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: the Bogalusa Heart Study. N Engl J Med 1998, 338: 1650-6.
20. Holvoet P, Kritchevsky SB, Tracy RP, et al. The metabolic syndrome, circulating oxidized LDL, and risk of myocardial infarction in well-functioning elderly people in the health, aging, and body composition cohort. Diabetes 2004, 53: 1068-73.
21. Iughetti L, Volta C, Maggi E, et al. Circulating antibodies recognizing oxidatively modified low-density lipoprotein in children. Pediatr Res 1999, 45: 94-9.
22. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Call Cardiol 2006, 47: 1803-10.
23. de Jongh S, Lilien MR, Bakker HD, Hutten BA, Kastelein JJ, Stroes ESG. Familial history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia. Atherosclerosis 2002, 163: 193-7.
24. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolemia. Lancet 2004, 363: 369-70.
25. American Heart Association. Diagnosis and treatment of primary hyperlipidemia in childhood: a joint statement for physicians by the committee on atherosclerosis and hypertension in childhood on the council of cardiovascular disease in the young and the nutrition committee. Circulation 1986, 74: 1181A-8A.
26. Shamir R, Fisher EA. Dietary therapy for children with hypercholesterolemia. Am Fam Physician 2000, 61: 675-86.
27. Williams CL, Haymen LL, Daniels SR, et al. Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Hearth Association. Circulation 2002, 106: 143-60.
28. American Academy of Pediatrics Committee on Nutrition: Statement on cholesterol. Pediatrics 1992, 90: 469-73.
29. Lifshitz F, Moses N. Growth failure. A complication of dietary treatment of hypercholesterolemia. Am J Dis Child 1989, 143: 537-42.
30. Vobecky JS, Vobecky J, Normand L. Risk and benefit of low fat intake in childhood. Ann Nutr Metab 1995, 39: 124-33.
31. Lapinleimu H, Viikari J, Jokinen E, et al. Prospective randomized trial in 1062 infants of diet low in saturated fat and cholesterol. Lancet 1995, 345: 471-6.
32. Simell O, Niinikoski H, Rönnemaa T, et al. Special Turku coronary Risk factor Intervention Project of Babies (STRIP). Am J Clin Nutr 2000, 72 (suppl 5): 1316S-31S.
33. Rask-Nissilä L, Jokinen E, Rönnemaa T, et al. Prospective, randomized, infancy-onset trial of the effects of a low-saturated-fat, low-cholesterol diet on serum lipids and lipoprotein before school age: The Special Turku Coronary Risk factor Intervention Project (STRIP). Circulation 2000, 102: 1477-83.
34. Kaitosaari T, Rönnemaa T, Raitakari O, et al. Effect of 7-year infancy-onset dietary intervention on serum lipoproteins and lipoprotein subclasses in healthy children in the prospective, randomized Special Turku Coronary Risk factor Intervention Project for children (STRIP) study. Circulation 2003, 108: 672-7.
35. DISC Collaborative Research Group. Dietary Intervention Study in Children (DISC) with elevated low-density-lipoprotein cholesterol. Design and baseline characteristics. Ann Epidemiol 1993, 3: 393-403.
36. The Writing Group for the DISC Collaborative Research Group. Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density-lipoprotein cholesterol: the Dietary Intervention Study in Children (DISC). JAMA 1995, 273: 1429-35.
37. Lauer RM, Obarzanek F, Hunsberger SA, et al. Efficacy and safety of lowering dietary intake of total fat, saturated fat, and cholesterol in children with elevated LDL cholesterol: the Dietary Intervention Study in Children. Am J Clin Nutr 2000, 72 (Suppl 5): 1332S-42S.
38. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children. Pediatrics 2001, 107: 256-64.
39. Sánchez-Bayle M, Soriano-Guillén L. Influence of dietary intervention on growth in children with hypercholesterolaemia. Acta Paediatr 2003, 92: 1043-6.
40. Poustie VJ, Rutherford P. Dietary treatment for familial hypercholesterolaemia. Cochrane Database Syst Rev 2001, 2: CD001918.
41. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992, 340: 1111-5.
42. Schaefer EJ. Lipoproteins, nutrition, and heart disease. Am J Clin Nutr 2002, 75: 191-212.
43. Mietus-Snyder M, Malloy MJ. Endothelial dysfunction occurs in children with three genetic hyperlipidemias: improvement with antioxidant therapy. J Pediatr 1998, 133: 35-40.
44. Raitakari OT, Celermajer DS. Testing for endothelial dysfunction. Ann Med 2000, 32: 293-304.
45. Cohen JD, Drury JH, Ostdiek J, et al. Benefits of lipid lowering on vascular reactivity in patients with coronary artery disease and average cholesterol levels: a mechanism for reducing clinical events? Am Heart J 2000, 139: 734-8.
46. Raitakari O, Rönnemaa T, Järvisalo MJ, et al. Endothelial function in healthy 11-year-old children after dietary intervention with onset in infancy: the Special Turku Coronary Risk Factor Intervention Project for children (STRIP). Circulation 2005, 112: 3786-94.
47. Engler MM, Engler MB, Malloy MJ, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation 2003, 108: 1059-63.
48. Lagström H, Seppänen R, Jokinen F, et al. Influence of dietary fat on the nutrient intake and growth of children from 1 to 5 years of age: the Special Turku coronary Risk factor Intervention Project. Am J Clin Nutr 1999, 69: 516-23.
49. Rask-Nissilä L, Jokinen E, Terho F, et al. Neurological development of 5-year-old children receiving a low-saturated fat, low-cholesterol diet since infancy: A randomized controlled trial. JAMA 2000, 284: 993-1000.
50. Hansen D, Michaelsen KF, Skovby F. Growth during treatment of familial hypercholesterolemia. Acta Paediatr 1992, 81: 1023-5.
51. Kaplan RM, Toshima MT. Does a reduced fat diet cause retardation in child growth? Prev Med 1992, 21: 33-52.
52. Lifshitz F, Tarim O. Considerations about dietary fat restrictions for children. J Nutr 1996, 126: 1031S-41S.
53. Jones PJ, Raeini-Sarjaz M, Ntanios FY, Vanstone CA, Feng JY, Parsons WE. Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters. J Lipid Res 2000, 41: 697-705.
54. Ostlund RE Jr. Phytosterols and cholesterol metabolism. Curr Opin Lipidol 2004, 15: 37-41.
55. Weststrate JA, Meijer GW. Plant sterol-enriched margarines and reduction of plasma total and LDL cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects. Eur J Clin Nutr 1998, 52: 334-43.
56. Gylling H, Siimes MA, Miettinen TA. Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia. J Lipid Res 1995, 36: 1807-12.
57. Vuorio AF, Gylling H, Turtola H, Kontula K, Ketonen P, Miettinen TA. Stanol ester margarine alone and with simvastatin lowers serum cholesterol in families with familial hypercholesterolemia caused by the FH-North Karelia mutation. Arterioscler Thromb Vasc Biol 2000, 20: 500-6.
58. Amundsen AL, Ose L, Nenseter MS, Ntanios FY. Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia. Am J Clin Nutr 2002, 76: 338-44.
59. de Jongh S, Vissers MN, Rol P, Bakker HD, Kastelein JJ, Stroes ES. Plant sterol lower LDL cholesterol without improving endothelial function in prepubertal children with familial hypercholesterolaemia. J Inherit Metab Dis 2003, 26: 343-51.
60. Hedman M, Matikainen T, Föhr A, et al. Efficacy and safety of pravastatin in children and adolescent with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study. J Clin Endocrinol Metab 2005, 90: 1942-52.
61. Jakulj L, Vissers MN, Rodenburg J, Wiegman A, Trip MD, Kastelein JJP. Plant stanol do not restore endothelial function in pre-pubertal children with familial hypercholesterolemia despite reduction of low-density lipoprotein cholesterol levels. J Pediatr 2006, 148: 495-500.
62. Amundsen AL, Ntanios F, Put N, Ose L. Long-term compliance and changes in plasma lipids, plant sterols and carotenoids in children and parents with FH consuming plant sterol ester-enriched spread. Eur J Clin Nutr 2004, 58: 1612-20.
63. Katan MB, Grundy SM, Jones F, Law M, Miettinen T, Paoletti R. Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. Mayo Clin Proc 2003, 78: 965-78.
64. Krauss RM, Eckel RH, Howard B, et al. AHA Dietary Guidelines. Revision 2000: A statement for healthcare professionals from the Nutrition Committee of the American Heart Association. Circulation 2000, 102: 2284-99.
65. Martino F, Martino E, Morrone F, Carnevali E, Forcone R, Niglio T. Effect of dietary supplementation with glucomannan on plasma total cholesterol and low density lipoprotein cholesterol in hypercholesterolemic children. Nutr Metab Cardiovasc Dis 2005, 15: 174-80.
66. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344: 1383-9.
67. Sprecher DL, Daniels SR. Rational approach to pharmacologic reduction of cholesterol levels in children. J Pediatr 1996, 129: 4-7.
68. Mordasini R, Twelsick F, Oster P, et al. A comparative study of colestipol and cholestyramine in children and adolescents with familial hypercholesterolemia. Monatsschr Kinderheilkd 1978, 126: 436-40.
69. Glueck CJ, Mellies MJ, Dine M, Perry T, Laskarzewski P. Safety and efficacy of long-term diet and diet plus bile acid-binding resin cholesterol-lowering therapy in 73 children heterozygous for familial hypercholesterolemia. Pediatrics 1986, 78: 338-48.
70. Stein EA. Treatment of familial hypercholesterolemia with drugs in children. Arteriosclerosis 1989, 9 (Suppl 1): 1145-51.
71. Schlierf G, Mrozik K, Heuck CC, et al. "Low dose" colestipol in children, adolescents and young adults with familial hypercholesterolemia. Atherosclerosis 1982, 41: 133-8.
72. Groot PHE, Dijkhuis-Stoffelsma R, Grose WFA, Ambagtsheer JJ, Fernandes J. The effects of colestipol hydrochloride on serum lipoprotein lipid and apolipoprotein B and A-I concentrations in children heterozygous for familial hypercholesterolemia. Acta Paediatr Scand 1983, 72: 81-5.
73. Tonstad S, Sivertsen M, Aksnes L, Ose L. Low dose colestipol in adolescents with familial hypercholesterolaemia. Arch Dis Child 1996, 74: 157-60.
74. Tonstad S, Ose L. Colestipol tablets in adolescents with familial hypercholesterolaemia. Acta Paediatr 1996, 85: 1080-2.
75. Glueck CJ, Tsang RC, Fallat RW, Mellies M. Therapy of familial hypercholesterolemia in childhood: diet and cholestyramine resin for 24 to 36 months. Pediatrics 1977, 59: 433-41.
76. West RJ, Lloyd JK, Leonard JV. Long-term follow-up of children with familial hypercholesterolaemia treated with cholestyramine. Lancet 1980, 2: 873-5.
77. Koletzko B, Kupke I, Wendel U. Treatment of hypercholesterolemia in children and adolescents. Acta Paediatr 1992, 81: 682-5.
78. Liacouras CA, Coates PM, Gallagher PR, Cortner JA. Use of cholestyramine in the treatment of children with familial combined hyperlipidemia. J Pediatr 1993, 122: 477-82.
79. Tonstad S, Knudtzon J, Sivertsen M, Refsum H, Ose L. Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia. J Pediatr 1996, 129: 42-9.
80. McCrindle BW, O'Neill MB, Cullen-Dean G, Helden E. Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial. J Pediatr 1997, 130: 266-73.
81. Hussein O, Frydman G, Frim H, Aviram M. Reduced susceptibility of low density lipoprotein to lipid peroxidation after cholestyramine treatment in heterozygous familial hypercholesterolemic children. Pathophysiology 2001, 8: 21-8.
82. Asami T, Uchiyama M. Treatment of children with familial hypercholesterolemia with colestilan, a newly developed bile acid-binding resin. Atherosclerosis 2002, 164: 381-2.
83. Shepherd J. Mechanism of action of bile acid sequestrants and other lipid-lowering drugs. Cardiology 1989, 76 (Suppl 1): 65-71.
84. Schwarz KB, Goldstein PD, Witztum JL, Schonfeld G. Fat-soluble vitamin concentrations in hypercholesterolemic children treated with colestipol. Pediatrics 1980, 65: 243-50.
85. Stampfer MJ, Malinow MR, Willett WC, et al. A prospective study of plasma homocysteine and risk of myocardial infarction in US physicians. JAMA 1992, 268: 877-81.
86. Ducobu J, Brasseur D, Chaudron JM, et al. Simvastatin use in children. Lancet 1992, 339: 1488.
87. Couture P, Brun LD, Szots F, et al. Association of specific LDL receptor gene mutations with differential plasma lipoprotein response to simvastatin in young French Canadians with heterozygous familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998, 18: 1007-12.
88. Stefanutti C, Lucani G, Vivenzio A, Di Giacomo S. Diet only and diet plus simvastatin in the treatment of heterozygous familial hypercholesterolemia in childhood. Drugs Exp Clin Res 1999, 25: 23-8.
89. de Jongh S, Ose L, Szamosi T, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized, double-blind, placebo-controlled trial with simvastatin. Circulation 2002, 106: 2231-7.
90. de Jongh S, Lilien MR, op't Roodt J, Stroes ES, Bakker HD, Kastelein JJ. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002, 40: 2117-21.
91. Vohl MC, Szots F, Lelièvre M, et al. Influence of LDL receptor gene mutation and apo E polymorphism on lipoprotein response to simvastatin treatment among adolescents with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 160: 361-8.
92. Dirisamer A, Hachemian N, Bucek RA, Wolf F, Reiter M, Widhalm K. The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation. Eur J Pediatr 2003, 162: 421-5.
93. Knipscheer HC, Boelen CC, Kastelein JJ, et al. Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia. Pediatr Res 1996, 39: 867-71.
94. Hedman M, Neuvonen PJ, Neuvonen M, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia. Clin Pharmacol Ther 2003, 74: 178-85.
95. Wiegman A, Hutten BA, de Groot E, et al. Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA 2004, 292: 331-7.
96. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJP, Sijbrands EJG. Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation 2005, 112: 3168-73.
97. Sinzinger H, Schmid P, Pirich C, et al. Treatment of hypercholesterolaemia in children. Lancet 1992, 340: 548-9.
98. Lambert M, Lupien PJ, Gagné C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics 1996, 97: 619-28.
99. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. J Am Med Assoc 1999, 281: 137-44.
100. Kwiterovich PO Jr. Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin. Nutr Metab Cardiovasc Dis 2001, 11 (Suppl. 5): 30-4.
101. Clauss SB, Holmes KW, Hopkins P, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics 2005, 116: 682-8.
102. Athyros VG, Papageorgiou AA, Kontopoulos AG. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis 2002, 163: 205-6.
103. McCrindle BW, Ose L, Marais AD. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipemia: a multicenter, randomized, placebo-controlled trial. J Pediatr 2003, 142: 74-80.
104. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interaction of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001, 57: 357-64.
105. Endo A. The discovery and development of HMG-CoA reductase inhibitors. 1992. Atheroscler Suppl 2004, 5: 67-80.
106. de Jongh S, Kerckhoffs MC, Grootenhuis MA, Bakker HD, Heymans HS, Last BF. Quality of life, anxiety and concerns among statin-treated children with familial hypercholesterolaemia and their parents. Acta Paediatr 2003, 92: 1096-101.
107. Sijbrands EJG, Lombardi MP, Westendorp RG, et al. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998, 136: 247-54.
108. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003, 349: 1157-67.
109. Hedman M, Antikainen M, Holmberg C, et al. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br J Clin Pharmacol 2006, 61: 706-15.
110. Niemi M, Schaeffeler E, Lang T, et al. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004, 14: 429-40.
111. Schuster H. Improving lipid management - to titrate, combine or switch. Int J Clin Pract 2004, 58: 689-94.
112. Jacobson TA. Statin safety: lessons from new drug applications for marketed statins. Am J Cardiol 2006, 97: 44C-51C.
113. McKenney JM, Davidson MH, Jacobson TA, Guyton JR; National Lipid Association Statin Safety Assessment Task Force. Final conclusion and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97: 89C-94C.
114. Corsini A, Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. New insights into the pharmacodynamics and pharmacokinetic properties of statins. Pharmacol Ther 1999, 84: 413-28.
115. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002, 36: 288-95.
116. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001, 16: 1545-9.
117. Bogman K, Peyer AK, Török M, Küsters E, Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001, 132: 1183-92.
118. Penson MG, Fricker FJ, Thompson JR, et al. Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients. J Heart Lung Transplant 2001, 20: 611-8.
119. Seipelt IM, Crawford SE, Rodgers S, et al. Hypercholesterolemia is common after pediatric heart transplantation: initial experience with pravastatin. J Heart Lung Transplant 2004, 23: 317-22.
120. Hedman M, Neuvonen PJ, Neuvonen M, Holmberg C, Antikainen M. Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004, 75: 101-9.
121. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol 1996, 10: 171-4.
122. Argent E, Kainer G, Aitken M, Rosenberg AR, Mackie FE. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant 2003, 7: 38-42.
123. Jacobson TA. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors. Am J Cardiol 2004, 94: 1140-6.
124. Drugs.com (http://www.drugs.com).
125. Gibbons LW, Gonzalez V, Gordon N, Grundy S. The prevalence of side effects with regular and sustained-release nicotinic acid. Am J Med 1995, 99: 378-85.
126. Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998, 81: 805-7.
127. Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. Pediatrics 1993, 92: 78-82.
128. National Cholesterol Education Program. Third report of the Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. NIH publication no. 01-3095. Bethesda: National Institutes of Health, 2001.
129. Steinmetz J, Morin C, Panek E, Siest G, Drouin P. Biological variations in hyperlipidemic children and adolescent treated with fenofibrate. Clin Chim Acta 1981, 112: 43-53.
130. Wheeler KAH, West RJ, Lloyd JK, Barley J. Double blind trial of bezafibrate in familial hypercholesterolaemia. Arch Dis Child 1985, 60: 34-7.
131. McCrindle BW, Helden E, Cullen-Dean G, Conner WT. A randomized crossover trial of combination pharmacologic therapy in children with familial hyperlipidemia. Pediatr Res 2002, 51: 715-21.
132. Hedman M, Miettinen TA, Gylling H, Ketomäki A, Antikainen M. Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy. J Pediatr 2006, 148: 241-6.
133. Knopp RH, Gitter H, Truitt T, et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur Heart J 2003, 24: 729-41.
134. Gagné C, Gaudet D, Bruckert E; Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002, 105: 2469-75.
135. Raal FJ, Marais AD, Klepack E, Lovalvo J, McLain R, Heinonen T. Avasimibe, an ACAT inhibitor, enhances the lipid lowering effect of atorvastatin in subjects with homozygous familial hypercholesterolemia. Atherosclerosis 2003, 171: 273-9.